Finally, since TGF-β is known to be a regulator of Treg and Th17-cell differentiation [41]–[44], we looked at its serum concentration, in CHC and NAFLD/NASH patients before and after NLCD, taking into account that TGF-β, as well as HA, is a predictor of clinical worsening [32]–[34]. The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatohepatitis.